Given the high stakes, the safety and efficacy of off-label use in neonates are closely monitored through various mechanisms. Neonatologists often rely on data from case studies, clinical guidelines, and registry data. Continuous monitoring and reporting of outcomes are essential to ensure that any adverse effects are quickly identified and managed.
